aTyr Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATYR research report →
Companywww.atyrpharma.com
aTyr Pharma, Inc. , a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
- CEO
- Sanjay S. Shukla
- IPO
- 2015
- Employees
- 56
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $52.03M
- P/E
- -0.74
- P/S
- 273.82
- P/B
- 0.90
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -11754.74%
- Op Margin
- -38573.68%
- Net Margin
- -36857.37%
- ROE
- -99.87%
- ROIC
- -105.54%
Growth & Income
- Revenue
- $190.00K · -19.15%
- Net Income
- $-74,118,000 · -15.77%
- EPS
- $-0.80 · 6.98%
- Op Income
- $-77,627,000
- FCF YoY
- 10.29%
Performance & Tape
- 52W High
- $7.29
- 52W Low
- $0.40
- 50D MA
- $0.80
- 200D MA
- $1.47
- Beta
- 0.66
- Avg Volume
- 1.82M
Get TickerSpark's AI analysis on ATYR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Coughlin Timothy | other | 50,000 |
| May 11, 26 | BENEVICH ERIC | other | 50,000 |
| May 11, 26 | Gross Jane A | other | 50,000 |
| May 11, 26 | Lucas Svetlana | other | 50,000 |
| May 11, 26 | Zaknoen Sara | other | 50,000 |
| May 11, 26 | SCHIMMEL PAUL | other | 50,000 |
| Feb 3, 26 | Shukla Sanjay | other | 10,375 |
| Feb 4, 26 | Shukla Sanjay | sell | 3,745 |
| Feb 3, 26 | Shukla Sanjay | other | 10,375 |
| Feb 3, 26 | Broadfoot Jill Marie | other | 3,750 |
Our ATYR Coverage
We haven't published any research on ATYR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATYR Report →